Next Article in Journal
Reexamining a Host-Associated Genomic Diversity of Bean Golden Mosaic Virus (BGMV) Isolates from Phaseolus Species and Other Fabaceae Hosts
Previous Article in Journal
Defining Soilborne Pathogen Complexes Provides a New Foundation for the Effective Management of Faba Bean Root Diseases in Ethiopia
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Trends of Antibiotic Resistance Patterns and Bacteriological Profiles of Pathogens Associated with Genitourinary Infections in Secondary Healthcare Facilities in the Volta Region of Ghana

1
School of Pharmacy, University of Health and Allied Sciences, Ho P.O. Box PMB 31, Ghana
2
Margret Marquart Catholic Hospital, Kpando P.O. Box. 97, Ghana
3
Volta Regional Hospital, Hohoe P.O. Box 27, Ghana
4
Ho Teaching Hospital, Ho P.O. Box MA 374, Ghana
5
Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London NW1 2PG, UK
6
Research Department of Practice and Policy, School of Pharmacy, University College London, London WC1N 1AX, UK
*
Author to whom correspondence should be addressed.
Pathogens 2025, 14(7), 696; https://doi.org/10.3390/pathogens14070696
Submission received: 23 May 2025 / Revised: 8 July 2025 / Accepted: 12 July 2025 / Published: 15 July 2025
(This article belongs to the Section Bacterial Pathogens)

Abstract

Urogenital infections contribute greatly to both hospital- and community-acquired infections. In Ghana, the prevalence of resistance to commonly used antibiotics is relatively high. This study sought to evaluate the antibiotic sensitivity of bacterial urogenital pathogens from patient samples in a regional and district hospital in the Volta Region of Ghana. A retrospective cross-sectional study was conducted using data obtained between January and December 2023 from Volta Regional Hospital and Margret Marquart Catholic Hospital. Bacteria were isolated from urine, urethral swabs, and vaginal swabs from 204 patients. Data on culture and sensitivity assays performed using the Kirby–Bauer disc diffusion method were extracted and analyzed using WHONET. The most prevalent organisms isolated from the samples from both facilities were Escherichia coli (24.9%), Staphylococcus aureus (21.5%), and Klebsiella oxytoca (8.8%). The isolates were mostly resistant to amoxicillin/clavulanic acid (n = 75, 95% CI [91.8–99.9]), meropenem (n = 61, 95% CI [87.6–99.4]), cefuroxime (n = 54, 95% CI [78.9–96.5]), ampicillin (n = 124, 95% CI [61.2–77.9]), and piperacillin (n = 43, 95% CI [82.9–99.2]). Multidrug-resistant (MDR, 70 (34.1%)), extensively drug-resistant (XDR, 63 (30.7%)), and pandrug-resistant (PDR, 9 (4.3%)) strains of S. aureus, E. coli, and Pseudomonas aeruginosa were identified from the patient samples. The study highlights the presence of high-priority resistant urogenital pathogens of public health significance to varied antibiotic groups.

1. Introduction

The escalating global spread of antimicrobial resistance (AMR) poses a serious threat to public health. In 2015, the World Health Organization (WHO) approved a Global Action Plan to tackle AMR and launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) [1]. These efforts targeted at curbing AMR promote antimicrobial stewardship, routine, and focused surveillance and the need for surveys and studies that support the timely detection, reporting, risk assessment, and monitoring of emerging resistance.
As bacteria develop resistance to antibiotics, the effectiveness of these essential treatments for the management of infectious diseases declines [2]. The overuse and prolonged use of antibiotics have created major challenges with resistant organisms, leading to higher rates of illness and death [3]. The resistant organisms may be classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR). MDR organisms are resistant to at least one agent in three or more antimicrobial categories, while XDR strains are resistant to at least one agent in all but two or fewer antimicrobial categories. Strains that are resistant to all antimicrobial agents in all antimicrobial categories are considered PDR [4]. It is estimated that the effectiveness of antibiotics is decreasing, with increasing resistance to both first-line and last-resort antibiotics, resulting in severe clinical, societal, and economic consequences [5]. As a result, drug-resistant pathogens have a profound effect on public health, economic stability, and global mortality rates, with microbial diseases causing a considerable number of deaths annually, according to WHO [6]. The growing prevalence of antibiotic-resistant bacteria is a major concern for both inpatient and outpatient care, especially given the slow development of new antimicrobials [7]. Pathogens such as Enterococcus faecium, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Enterobacter spp. are closely monitored due to their resistance to various antibacterial agents [8,9].
Surveillance of resistance in bacterial species is core to overcoming the burden of AMR [10]. The selection of antibacterials for empiric and definitive therapy relies on well-curated data on the resistance profiles of bacterial co-infections in various diseases. Urogenital infections are made up of a spectrum of urinary tract-related infections, from asymptomatic bacteriuria and cystitis to pyelonephritis and urosepsis [11]. Urinary tract infections (UTI) are among the most common nosocomial and community-acquired infections affecting both the elderly and adults of reproductive age [12]. These infections are associated with several risk factors like comorbid diseases, functional status, and living environments. Evaluation of the antibiotic susceptibility profiles of urogenital pathogens has been associated with increased antibiotic efficacy and appropriate antibiotic selection for management of these genitourinary infections.
An antibiogram is an important resource in healthcare, offering a periodic overview of the antimicrobial susceptibility of bacterial isolates [13,14]. Clinicians use antibiograms to evaluate local susceptibility rates, compare these rates with other institutions, guide the selection of empiric antibiotic treatments, and track resistance trends over time within their facility. Therefore, the aim of this work was to assess the antibiotic susceptibility profiles of urogenital pathogens isolated from urogenital infections in secondary healthcare facilities in the Volta Region of Ghana.

2. Materials and Methods

2.1. Study Site

This study was carried out at the Volta Regional Hospital (VRH), Hohoe, and the Margret Marquart Catholic Hospital (MMCH), Kpando (Figure 1). These hospitals are secondary healthcare facilities that serve the health needs of patients in the upper belt of the Volta Region of Ghana. These facilities together have more than 300 beds and functional microbiology laboratories that conduct routine isolation and characterization of bacteria co-infecting varied disease conditions.

2.2. Study Design

This was a retrospective cross-sectional study utilizing reports from the Lightwave Health Information Management System and the laboratory data register on all isolated urogenital micro-organisms in VRH and MMCH. Laboratory data on the culture and sensitivity of bacterial isolates from January 2023 to December 2023 were assessed. The microbiology laboratory receives urogenital specimens, including vaginal swabs, urine, and urethral swabs. The bacteriological analysis of these samples included enrichment and culturing of pathogens of interest employing national standard operating procedures and guidelines from the 33rd edition of the performance standards for antimicrobial susceptibility testing by the Clinical and Laboratory Standards Institute (CLSI, 2023 [15]). Bacteria were enriched in blood agar. Routine biochemical assays were performed using triple-sugar iron broth, lysine iron agar, urea media, oxidase reagent, and analytical profile index (API) 20E for Enterobacterales; these were all obtained from Oxoid Limited (Basingstoke, UK). Quality control was performed with standard microbial strains, such as Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 8739), Pseudomonas aeruginosa (ATCC 27853), Proteus mirabilis (ATCC 12453), Haemophilus influenza (ATCC 9027), and Enterococcus faecalis (ATCC 29212), and culture and sensitivity testing was performed using the Kirby–Bauer disc diffusion method employing CLSI breakpoints [15].

2.3. Inclusion Criteria and Exclusion Criteria

All urogenital microbiological specimen entries from January 2023 to December 2023 with information on patient age, gender, ward, outpatient/inpatient status, specimen type, and antibiotic culture and sensitivity results of bacterial isolates implicated in suspected infections were included in the study. The data set excluded viral strains, fungal strains, and other infectious protozoal pathogens.

2.4. Statistical Analysis

Microsoft Excel (Version 16), Origin Pro (2025), and WHONET software (2024), developed by the WHO Collaborating Centre for Surveillance of Antimicrobial Resistance, were used to analyze the data. Data were analyzed using tables, graphs, and charts. The prevalence of the isolates from the samples was calculated by analysis of isolate frequency per patient. The percentage susceptibility of the isolates was also determined at a 95% confidence interval for each isolate type of infectious pathogen isolated. A clustering heatmap using group average as a clustering method was used to assess the similarity in antibiotic response between the urogenital pathogens.

3. Results

3.1. Distribution of Bacterial Isolates in Characteristic Patient Groups

A total of 205 specimens from 204 patients with positive culture tests obtained from both facilities met the inclusion criteria and were included in the study (Table 1). Twenty-five distinct bacterial species belonging to 12 bacterial genera were identified in the samples, of which 11 were Gram-positive while 14 were Gram-negative. Staphylococcus aureus (n = 44, 21.5%) and Escherichia coli (n = 51, 24.9%) were the most prevalent bacterial isolates from both hospital facilities. Samples from which positive bacterial cultures were obtained from both facilities were urine (n = 105), vaginal (n = 87), and urethral swabs (n = 13). S. aureus was the most isolated organism from urethral and vaginal samples. E. coli and Klebsiella oxytoca were more prevalent in the urine samples from both study facilities. Pseudomonas aeruginosa was identified in urine samples from five patients. Neisseria gonorrhoeae was found in urethral swabs (n = 1) and vaginal swabs (n = 2).
There was a higher prevalence of urogenital pathogens in outpatient (88.3%) compared to inpatient urogenital samples. The isolates from VRH and the MMCH each showed a similar distribution to the total sample distribution from both facilities. Escherichia coli was the most isolated organism from the MMCH, while Staphylococcus aureus was the most predominant isolate from samples from the VRH (Figure 2A). Klebsiella oxytoca, Staphylococcus saprophyticus, Klebsiella sp., Streptococcus pyogenes, and Pseudomonas aeruginosa were also common in inpatient samples from both facilities (Figure 2B).
About 73% of the samples were obtained from females, while 27% of the samples were from males. Bacterial isolates were predominantly obtained from patients between the ages of 25 and 34 years for both genders. Female samples had a higher prevalence of E. coli, Klebsiella oxytoca, Staphylococcus aureus, Staphylococcus saprophyticus, and Streptococcus pyogenes compared to the samples obtained from males (Figure 3).

3.2. The Antibiotic Resistance Patterns of Bacterial Isolates

The isolated urogenital pathogens were tested against a total of 21 antibiotics using a standardized Kirby–Bauer disc diffusion assay according to guidelines from the 33rd edition (2023 version) of the performance standards for antimicrobial susceptibility testing of the Clinical and Laboratory Standards Institute (CLSI). The results, however, excluded organisms that are intrinsically resistant to the tested antibiotics [16]. Overall, the isolates were most resistant to amoxicillin/clavulanic acid (n = 75, 95% CI [91.8–99.9]), meropenem (n = 61, 95% CI [87.6–99.4]), cefuroxime (n = 54, 95%CI [ 78.9–96.5]), and piperacillin (n = 43, 95% CI [82.9–99.2]). Amikacin (n = 135, 95% CI [5.4–16.2], gentamicin (n = 146, 95% CI [22.4–37.7]), levofloxacin (n = 200, 95% CI [24.2–40.2], and cefotaxime (n = 68, 40% CI [27–50.9] were the most active antibiotics against all the bacterial isolates from both facilities.
Ciprofloxacin (n = 200), tetracycline (n = 185), gentamicin (n = 146), and trimethoprim/sulfamethoxazole (n = 151) were the antibiotics that were frequently tested against the isolated pathogens. Piperacillin, ampicillin, ampicillin/sulbactam, amikacin, nitrofurantoin, ciprofloxacin, and erythromycin all showed greater activity against test isolates from the VRH compared to the MMCH. Levofloxacin, chloramphenicol, and vancomycin were more active against isolates from MMCH compared to VRH.
Of the 21 antibiotics tested, amikacin was the most active against E. coli, K. oxytoca, S. aureus, and P. aeruginosa isolates from both hospitals. Gentamicin showed the highest activity (n = 91%) against Streptococcus pyogenes, S. aureus, and E. coli isolates had no sensitivity to ampicillin/sulbactam and amoxicillin/clavulanic acid. Norfloxacin and chloramphenicol also showed no activity against the S. aureus isolates (Table S1). Piperacillin, amoxicillin/clavulanic acid, and tetracycline were not active against the E. coli isolates. Meropenem was also not active against any of the P. aeruginosa isolates. Meropenem also showed no activity against all the isolated urogenital pathogens except E. coli.
The activity of the antibiotics against the isolated urogenital pathogens was clustered into two groups (Figure 4). Gentamicin, amikacin, chloramphenicol, norfloxacin, levofloxacin, ciprofloxacin, cefotaxime, and ceftriaxone were distributed into the group one cluster, while the other antibiotics were also distributed into a separate cluster. At a similarity of 98%, meropenem and amoxicillin showed similar activity profiles against the isolated urogenital pathogens. The most active antibiotics clustered in group one, while the second cluster contained antibiotics that were less effective against the urogenital pathogens. There was about 50% similarity in the sensitivity profiles of E. coli and K. oxytoca to the antibiotics tested.
A significant prevalence of MDR, XDR, and PDR strains of S. aureus, E. coli, and P. aeruginosa was observed in the clinical specimens. A total of 70 MDR, 63 XDR, and 9 PDR strains were identified; 75% (n = 38) and 65% (n = 33) of the E. coli isolates were MDR and XDR, respectively, while one PDR strain was isolated. One PDR strain of P. aeruginosa was also isolated from the urogenital samples. Of the total S. aureus isolates, 66% were MDR, while 61% and 16% were XDR and PDR strains, respectively. Additionally, a striking 65% of Klebsiella spp. were identified as XDR.
The data also indicated a high incidence of extended-spectrum β-lactamase (ESBL)-producing (n = 68) Enterobacterales, carbapenem-resistant Enterobacterales (CRE) (n = 19), and vancomycin-resistant Staphylococcus spp. (Table S2).

4. Discussion

Surveillance plays a critical role in antimicrobial stewardship by providing essential data that informs and guides effective interventions and policies to combat AMR. Surveillance efforts help in epidemiological data collection, identification of resistance patterns, and outbreak detection. These efforts inform appropriate selection of antimicrobials for empiric and definitive therapy [17]. Global efforts made by networks such as the WHO GLASS, Africa Centers for Disease Control and Prevention’s AMR surveillance network, and other initiatives by partner organizations have a primary focus on pathogen surveillance and characterization. The use of bacteria prevalence studies in the clinical setting is indispensable in managing bacterial infections and safeguarding the efficacy of antibiotics. Clinicians make better choices for empiric therapy when local bacterial prevalence studies are available. According to Cressman and colleagues, empiric antibiotic treatment should effectively cover approximately 80% of expected bacteria in non-critically ill patients and 90% in critically ill patients [18].
Urogenital infections form a major part of nosocomial and community-acquired infections [19]. Urogenital pathogens are associated with generalized UTI, cystitis, gonorrhea, syphilis, chlamydiosis, and trichomoniasis. In most secondary healthcare facilities in Ghana, antibiotic selection for the management of UTI is empiric [20]. The study thus focused on assessing the trend of antibiotic resistance in bacterial urogenital pathogens from district-level facilities in the Volta region of Ghana.
Findings from this study revealed a high proportion of isolates from female patients. This could be because women have a better health-seeking behaviour, hence resulting in thorough bacteriological screening of suspected infections during hospital visits [21]. These findings are comparable to those reported by Ahabwe and colleagues, who also isolated a substantial proportion (62%) of bacterial isolates from women. Women are also more prone to UTIs due to their anatomical characteristics [22,23]. This may have accounted for the high number of urogenital pathogens in the samples from both hospitals. Most of the isolates were also obtained from patients predominantly in their reproductive age range, likely due to reproductive-age-related urinary tract infections like candidiasis, gonorrhea, chlamydia, syphilis, and trichomoniasis, which may require regular hospital visits and screening [24,25]. Bacterial vaginosis, gonorrhea, pelvic inflammatory disease, and UTI are associated with urogenital pathogens such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Staphylococcus saprophyticus, and Neisseria gonorrhoeae, and these urogenital pathogens were also prevalent in the urogenital samples from both facilities [26,27,28,29].
The source clinical samples were urine, urethral swabs, and vaginal swabs. Urine and vaginal swab isolates were the most predominant. This indicates the presentation of cases of both symptomatic and asymptomatic bacteriuria, urethritis, and vaginosis in both hospitals. Globally, UTIs represent almost 10% of all infection cases in hospitalized patients, which makes them the second most common cause of emergency admission, and can infect various parts of the urinary system, including the bladder (cystitis), kidneys (pyelonephritis), and urethra (urethritis) [19,30,31]. Escherichia coli, Staphylococcus aureus, and Klebsiella oxytoca were the most common bacterial isolates from urine. Though S. aureus is less commonly isolated from urine samples compared to E. coli, its presence is more commonly seen in patients with underlying health conditions such as diabetes or those who are immunocompromised [11,32]. Streptococcus pyogenes was also isolated from vaginal samples. Though this pathogen frequently colonizes the respiratory tract, it can occasionally colonize the vaginal tract when there is dysbiosis in the vaginal flora [25,28,33].
Antibacterials account for 73–93% of all anti-infectives used by hospital facilities in the Volta Region [34]. In the current study, urogenital pathogenic bacterial isolates from the various sample types were resistant to most of the commonly used antibacterials. The resistance of the pathogens to β-lactam antibacterials such as penicillins, carbapenems, and cephalosporins is particularly worrying since these antibacterials form a major part of the routine prescribing of antibacterials for empiric therapy in the study region. These findings are consistent with antibacterial susceptibility data emerging from the major referral center in the same region and other hospital facilities in Ghana [25,35,36,37].
Most antibiotics in the ‘Access’ group of the WHO AWaRe classification were also found to be less potent against most of the pathogens targeted [38]. However, amikacin and gentamicin showed a high potency against both Gram-positive and Gram-negative isolates from both hospitals. The ‘Watch’ category of antibacterials, such as piperacillin, meropenem, cefuroxime, and vancomycin, showed low activity against the study bacterial strains. This is particularly worrying since these antibacterials are less frequently used in these hospitals. Resistance to these less readily available and used antibacterials may be caused by cross-resistance of antibiotic resistance determinants such as plasmids, transposons, and integrons among antibacterials of the same class [39,40]. Amikacin, gentamicin, and levofloxacin were the most effective antibiotics against the urogenital pathogenic bacterial isolates. The low resistance of common pathogens to these antibacterials has been highlighted by various studies across the African sub-region [10].
There was a high prevalence of ESBL-producing Enterobacterales (n = 68), carbapenem-resistant Enterobacterales (CRE), and vancomycin-resistant staphylococci. Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) poses a significant global health challenge as it frequently causes the failure of empirical antibiotic therapy. The high resistance in these pathogens may be mediated by antibiotic resistance genotypes such as CTX-M, TEM, and SHV variants [41]. The E. coli and K. pneumoniae-derived CTX-M genotype is one of the major types of ESBLs. These may be disseminated by mobile genetic elements among the bacterial population. Carbapenems are considered the antibiotics of choice for the treatment of serious infections caused by ceftriaxone-resistant Enterobacterales [41]. This surge in CRE is mostly driven by the emergence and spread of variants of carbapenemases such as metallo-β-lactamase IMP, VIM, and KPC type variants [42]. The occurrence of MDR, XDR, and PDR strains may be due to inappropriate and indiscriminate use of antibiotics and horizontal transfer of resistance genes in bacteria [43]. These resistant strains have significant public health implications, and further studies are therefore needed to establish the cause and impact of this occurrence in the study hospitals.
The data presented in this study are fundamental to antimicrobial resistance surveillance at the district level in the study region. However, there are pertinent limitations that need to be addressed. Both facilities should make efforts to isolate and test pathogens against all the routinely used antibacterials. This is because some bacterial isolates were tested only against a few antimicrobials, which may skew the resistance data. Also, the facilities should ensure samples are collected before antibiotic therapy since prior antibiotic treatment before sample collection may over-stress the overall antimicrobial resistance outlook for the facility. Another limitation was that some of the bacterial isolates were not identified at the species level due to resource limitations in both facilities. The resource limitations restricted pathogen identification during routine culture and sensitivity testing to the use of biochemical assays. Also, the reliance on antibiotic multidiscs for routine culture and sensitivity tests may lead to testing the sensitivity of isolates to antibiotics that they are intrinsically resistant to.

5. Conclusions

The findings from the study indicated a high prevalence of E. coli and S. aureus in the study samples. Most of the isolates from these samples showed great susceptibility to amikacin, gentamicin, and levofloxacin, while high resistance was observed in the β-lactam group of antibiotics. The high prevalence of WHO priority organisms such as vancomycin-resistant Enterococcus, ESBL-E, and CRE highlights the need for both facilities to be zoned in as a hotspot for AMR surveillance efforts.
Given that AMR is a worldwide issue that calls for international cooperation to solve, it is critical that AMR surveillance data be produced in order to give stakeholders and healthcare professionals some information to aid in decision-making. Particular difficulties exist in sub-Saharan Africa, where the majority of medical facilities lack enough funding, and some patients cannot afford even the most basic culture and sensitivity tests. Ministries of health should, however, make an effort to cover a portion of these expenses in order to eliminate or lower patient costs. Incorporating molecular diagnostics into these tests will also be crucial for improved pathogen and resistance identification.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens14070696/s1, Table S1: Resistance pattern of pathogens isolated from sample types from both facilities; Table S2: Public health alerts—Important species and resistance of isolates (WHO Global Priority List of Antibiotic-Resistant Bacteria).

Author Contributions

Conceptualization: C.C.D., H.O., and Y.H.J.; methodology: C.C.D., H.O., N.O., B.A., K.D., G.V., and D.M.; data analysis: C.C.D., H.O., N.O., B.A., K.D., G.V., D.M., and R.S.; writing—original draft: C.C.D. and H.O.; writing—review and editing: J.J., A.H.-N., S.O.S., E.O., P.P., Y.H.J., I.O.B., T.A.A., R.S., Y.H.J., and P.P. All authors have read and agreed to the published version of the manuscript.

Funding

This project and APC were funded by the UK Department of Health and Social Care under the Commonwealth Partnerships for Antimicrobial Stewardship Scheme (Grant ID: Cw2 A.10).

Institutional Review Board Statement

Ethical clearance (GHS-ERC: 024/08/23, approval date: 9 October 2023) was obtained from the Ghana Health Service Ethics Review Committee. Permission was also sought from the management of both hospitals before the commencement of the research.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during this study have been included in this article.

Acknowledgments

We would like to acknowledge the assistance of the laboratory staff from Volta Regional Hospital and Margret Marquart Catholic Hospital.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
CLSIClinical and Laboratory Standards Institute
CREcarbapenem-resistant Enterobacterales
ESBLextended-spectrum β-lactamase
GLASSGlobal Antimicrobial Resistance and Use Surveillance System
MDRMultidrug resistant
MMCHMargret Marquart Catholic Hospital
PDRPandrug resistant
UTIUrinary tract infections
VRHVolta Regional Hospital
WHOWorld Health Organization
XDRExtensively drug-resistant

References

  1. WHO. Global Antimicrobial Resistance and Use Surveillance System (GLASS); World Health Organization: Geneva, Switzerland, 2022. [Google Scholar]
  2. Urban-Chmiel, R.; Marek, A.; Stępień-Pyśniak, D.; Wieczorek, K.; Dec, M.; Nowaczek, A.; Osek, J. Antibiotic Resistance in Bacteria—A Review. Antibiotics 2022, 11, 1079. [Google Scholar] [CrossRef] [PubMed]
  3. Chinemerem Nwobodo, D.; Ugwu, M.C.; Oliseloke Anie, C.; Al-Ouqaili, M.T.; Chinedu Ikem, J.; Victor Chigozie, U.; Saki, M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. J. Clin. Lab. Anal. 2022, 36, e24655. [Google Scholar] [CrossRef] [PubMed]
  4. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.J.C.M.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
  5. Ahmad, N.; Joji, R.M.; Shahid, M. Evolution and implementation of One Health to control the dissemination of antibiotic-resistant bacteria and resistance genes: A review. Front. Cell. Infect. Microbiol. 2023, 12, 1065796. [Google Scholar] [CrossRef]
  6. WHO. WHO Statistical Report 2020; World Health Organization: Geneva, Switzerland, 2020. [Google Scholar]
  7. Wozniak, R.A.F.; El-Herte, R. Editorial: Women in antimicrobial resistance and new antimicrobial drugs. Front. Cell. Infect. Microbiol. 2023, 13, 1263568. [Google Scholar] [CrossRef]
  8. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1–12. [Google Scholar] [CrossRef]
  9. Pendleton, J.N.; Gorman, S.P.; Gilmore, B.F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti-Infect. Ther. 2013, 11, 297–308. [Google Scholar] [CrossRef]
  10. Gahimbare, L.; Muvunyi, C.M.; Guessennd, N.A.K.; Rutanga, J.P.; Gashema, P.; Fuller, W.; Mwamelo, A.J.; Coulibaly, S.O.; Mosha, F.S.; Perovic, O.; et al. Antimicrobial Resistance in the WHO African Region: A Systematic Literature Review 2016–2020. Antibiotics 2024, 13, 659. [Google Scholar] [CrossRef]
  11. Alshomrani, M.K.; Alharbi, A.A.; Alshehri, A.A.; Arshad, M.; Dolgum, S. Isolation of Staphylococcus aureus Urinary Tract Infections at a Community-Based Healthcare Center in Riyadh. Cureus 2023, 15, e35140. [Google Scholar] [CrossRef]
  12. Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284. [Google Scholar] [CrossRef]
  13. Atif, M.; Naseem, M.; Sarwar, S.; Mukhtar, S.; Malik, I.; Hassan, M.R.U.; Iqbal, M.N.; Ahmad, N. Spectrum of Microorganisms, Antibiotic Resistance Pattern, and Treatment Outcomes Among Patients with Empyema Thoracis: A Descriptive Cross-Sectional Study From the Bahawal Victoria Hospital Bahawalpur, Punjab, Pakistan. Front. Med. 2021, 8, 665963. [Google Scholar] [CrossRef] [PubMed]
  14. Klinker, K.P.; Hidayat, L.K.; DeRyke, C.A.; DePestel, D.D.; Motyl, M.; Bauer, K.A. Antimicrobial stewardship and antibiograms: Importance of moving beyond traditional antibiograms. Ther. Adv. Infect. Dis. 2021, 8, 20499361211011373. [Google Scholar] [CrossRef] [PubMed]
  15. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Malvern, PA, USA, 2023. [Google Scholar]
  16. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Expected Resistant Phenotypes V 1.2. 2023. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Expert_Rules/2023/Expected_Resistant_Phenotypes_v1.2_20230113.pdf (accessed on 16 June 2025).
  17. Global Antimicrobial Resistance and Use Surveillance System (GLASS) report. Antibiotic use data for 2022. In WHO Library Cataloguing-in-Publication Data; World Health Organization: Geneva, Switzerland, 2025. [Google Scholar]
  18. Cressman, A.M.; Macfadden, D.R.; Verma, A.A.; Razak, F.; Daneman, N. Empiric antibiotic treatment thresholds for serious bacterial infections: A scenario-based survey study. Clin. Infect. Dis. 2019, 69, 930–937. [Google Scholar] [CrossRef] [PubMed]
  19. Kim, D.S.; Lee, J.W. Urinary Tract Infection and Microbiome. Diagnostics 2023, 13, 1921. [Google Scholar] [CrossRef]
  20. Adjapong, G.N.Y. Characterisation of Candida Species: A Case Study in Three Teaching Hospitals in Ghana. Ph.D. Thesis, School of Biological Sciences, University of Canterbury, Christchurch, New Zealand, 2014; pp. 10–15. [Google Scholar]
  21. Foxman, B. Urinary tract infection syndromes. Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. N. Am. 2014, 28, 1–13. [Google Scholar] [CrossRef]
  22. Ahabwe, O.M.; Kabanda, T.; Abesiga, L.; Mugisha, J.; Kayondo, M.; Ngonzi, J.; Tugume, R.; Agaba, C.D.; Byamukama, O.; Tibaijuka, L.; et al. Bacterial isolates and antibiotic susceptibility among women with abnormal vaginal discharge attending the gynecology clinic at a tertiary hospital in southwestern Uganda: A cross-sectional study. BMC Women’s Health 2023, 23, 572. [Google Scholar] [CrossRef]
  23. Kushnirenko, S.V.; Kushnirenko O., V. Urinary tract infections: Diagnosis and treatment, updates 2022. Ukr. J. Health Woman. 2023, 1, 64–70. [Google Scholar] [CrossRef]
  24. Gautron, J.M.C.; Thanh, G.T.; Barasa, V.; Voltolina, G. Using intersectionality to study gender and antimicrobial resistance in low- and middle-income countries. Health Policy Plan. 2023, 38, 1017–1032. [Google Scholar] [CrossRef]
  25. Walana, W.; Vicar, E.K.; Kuugbee, E.D.; Sakida, F.; Yabasin, I.B.; Faakuu, E.; Amfoabegyi, S.; Ziem, J.B. Antimicrobial resistance of clinical bacterial isolates according to the WHO’s AWaRe and the ECDC-MDR classifications: The pattern in Ghana’s Bono East Region. Front. Antibiot. 2023, 2, 1291046. [Google Scholar] [CrossRef]
  26. Carter, K.A.; Balkus, J.E.; Anzala, O.; Kimani, J.; Hoffman, N.G.; Fiedler, T.L.; Mochache, V.; Fredricks, D.N.; McClelland, R.S.; Srinivasan, S. Associations Between Vaginal Bacteria and Bacterial Vaginosis Signs and Symptoms: A Comparative Study of Kenyan and American Women. Front. Cell. Infect. Microbiol. 2022, 12, 801770. [Google Scholar] [CrossRef]
  27. Jennings, L.K.; Krywko, D.M. Pelvic Inflammatory Disease-StatPearls-NCBI Bookshelf; NCBI: Bethesda, MD, USA, 2023. [Google Scholar]
  28. Mulu, W.; Yimer, M.; Zenebe, Y.; Abera, B. Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot referral Hospital, Ethiopia: A cross sectional study. BMC Women’s Health 2015, 15, 42. [Google Scholar] [CrossRef] [PubMed]
  29. Wong, E.S.; Fennell, C.L.; Stamm, W.E. Urinary tract infection among women attending a clinic for sexually transmitted diseases. Sex. Transm. Dis. 1984, 11, 18–23. [Google Scholar] [CrossRef]
  30. Woldemariam, H.K.; Geleta, D.A.; Tulu, K.D.; Aber, N.A.; Legese, M.H.; Fenta, G.M.; Ali, I. Common urogenital pathogens and their antibiotic susceptibility pattern among diabetic patients. BMC Infect. Dis. 2019, 19, 43. [Google Scholar] [CrossRef]
  31. Pereira de Lima, M.A.; de Melo Gonçalves, I.B.; Ferreira Amorim, R.D.; Cândido Pimentel, J.V. Atypical pathogens in urinary tract infections: A systematic review. J. Microbiol. Exp. 2022, 10, 74–88. [Google Scholar] [CrossRef]
  32. Feglo, P. Prevalence and Antifungal Susceptibility Patterns of Yeast Isolates at the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. Br. Microbiol. Res. J. 2012, 2, 10–22. [Google Scholar] [CrossRef]
  33. Brouwer, S.; Rivera-Hernandez, T.; Curren, B.F.; Harbison-Price, N.; De Oliveira, D.M.; Jespersen, M.G.; Davies, M.R.; Walker, M.J. Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat. Rev. Microbiol. 2023, 21, 431–447. [Google Scholar] [CrossRef]
  34. Dodoo, C.C.; Orman, E.; Alalbila, T.; Mensah, A.; Jato, J.; Mfoafo, K.A.; Folitse, I.; Hutton-Nyameaye, A.; Okon Ben, I.; Mensah-Kane, P.; et al. Antimicrobial prescription pattern in Ho Teaching Hospital, ghana: Seasonal determination using a point prevalence survey. Antibiotics 2021, 10, 199. [Google Scholar] [CrossRef]
  35. Newman, M.J.; Frimpong, E.; Donkor, E.S.; Opintan, J.A.; Asamoah-Adu, A. Resistance to antimicrobial drugs in Ghana. Infect Drug Resist. 2011, 4, 215–220. [Google Scholar]
  36. Odoi, H.; Boamah, V.E.; Duah Boakye, Y.; Dodoo, C.C.; Agyare, C. Sensitivity Patterns, Plasmid Profiles and Clonal Relatedness of Multi-Drug Resistant Pseudomonas aeruginosa Isolated From the Ashanti Region, Ghana. Env. Health Insights 2022, 16, 11786302221078117. [Google Scholar] [CrossRef]
  37. Dodoo, C.C.; Odoi, H.; Mensah, A.; Asafo-Adjei, K.; Ampomah, R.; Obeng, L.; Jato, J.; Hutton-Nyameaye, A.; Aku, T.A.; Somuah, S.O.; et al. Development of a local antibiogram for a teaching hospital in Ghana. JAC Antimicrob. Resist. 2023, 5, dlad024. [Google Scholar] [CrossRef]
  38. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. In WHO Library Cataloguing-in-Publication Data; World Health Organization: Geneva, Switzerland, 2022. [Google Scholar]
  39. Wallace, V.J.; Sakowski, E.G.; Preheim, S.P.; Prasse, C. Bacteria exposed to antiviral drugs develop antibiotic cross-resistance and unique resistance profiles. Commun. Biol. 2023, 6, 837. [Google Scholar] [CrossRef] [PubMed]
  40. Colclough, A.; Corander, J.; Sheppard, S.K.; Bayliss, S.C.; Vos, M. Patterns of cross-resistance and collateral sensitivity between clinical antibiotics and natural antimicrobials. Evol. Appl. 2019, 12, 878–887. [Google Scholar] [CrossRef] [PubMed]
  41. Husna, A.; Rahman, M.M.; Badruzzaman, A.T.M.; Sikder, M.H.; Islam, M.R.; Rahman, M.T.; Alam, J.; Ashour, H.M. Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities. Biomedicines 2023, 11, 2937. [Google Scholar] [CrossRef] [PubMed]
  42. Queenan, A.M.; Bush, K. Carbapenemases: The versatile β-lactamases. Clin. Microbiol. Rev. 2007, 20, 440–458. [Google Scholar] [CrossRef]
  43. Alkofide, H.; Alhammad, A.M.; Alruwaili, A.; Aldemerdash, A.; Almangour, T.A.; Alsuwayegh, A.; Almoqbel, D.; Albati, A.; Alsaud, A.; Enani, M. Multidrug-resistant and extensively drugresistant enterobacteriaceae: Prevalence, treatments, and outcomes—A retrospective cohort study. Infect. Drug Resist. 2020, 13, 4653–4662. [Google Scholar] [CrossRef]
Figure 1. A map of the Volta Region showing the location of the study sites.
Figure 1. A map of the Volta Region showing the location of the study sites.
Pathogens 14 00696 g001
Figure 2. A graph showing the organism distribution by comparing the number of isolates: (A) by department (i.e., Inpatient and Outpatient Departments) in the study sites; (B) by facility (i.e., Margret Marquart Catholic Hospital and Volta Regional Hospital). Escherichia coli (eco); Pseudomonas aeruginosa (pae); Klebsiella sp. (kl-); Citrobacter sp. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus ss. aureus (sau) Citrobacter koseri (cdi); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae ss. pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. saprophyticus (sap); Citrobacter freundii (cfr); Enterobacter sp. (en-); Morganella morganii ss. Morganii (mmo); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy); Staphylococcus spp. (sta); Gardnerella vaginalis (gva); Streptococcus spp. (str); Enterococcus faecalis (efa); Streptococcus, non-haemolytic (gamma) (sgm).
Figure 2. A graph showing the organism distribution by comparing the number of isolates: (A) by department (i.e., Inpatient and Outpatient Departments) in the study sites; (B) by facility (i.e., Margret Marquart Catholic Hospital and Volta Regional Hospital). Escherichia coli (eco); Pseudomonas aeruginosa (pae); Klebsiella sp. (kl-); Citrobacter sp. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus ss. aureus (sau) Citrobacter koseri (cdi); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae ss. pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. saprophyticus (sap); Citrobacter freundii (cfr); Enterobacter sp. (en-); Morganella morganii ss. Morganii (mmo); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy); Staphylococcus spp. (sta); Gardnerella vaginalis (gva); Streptococcus spp. (str); Enterococcus faecalis (efa); Streptococcus, non-haemolytic (gamma) (sgm).
Pathogens 14 00696 g002
Figure 3. A graph showing the distribution of isolates by gender. The number of isolates per microorganism obtained from samples taken from males and females visiting the study sites with genitourinary infections. Escherichia coli (eco); Pseudomonas aeruginosa (pae); Klebsiella sp. (kl-); Citrobacter sp. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus ss. aureus (sau) Citrobacter koseri (cdi); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae ss. pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. saprophyticus (sap); Citrobacter freundii (cfr); Enterobacter sp. (en-); Morganella morganii ss. Morganii (mmo); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy); Staphylococcus spp. (sta); Gardnerella vaginalis (gva); Streptococcus spp. (str); Enterococcus faecalis (efa); Streptococcus, non-haemolytic (gamma) (sgm).
Figure 3. A graph showing the distribution of isolates by gender. The number of isolates per microorganism obtained from samples taken from males and females visiting the study sites with genitourinary infections. Escherichia coli (eco); Pseudomonas aeruginosa (pae); Klebsiella sp. (kl-); Citrobacter sp. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus ss. aureus (sau) Citrobacter koseri (cdi); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae ss. pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. saprophyticus (sap); Citrobacter freundii (cfr); Enterobacter sp. (en-); Morganella morganii ss. Morganii (mmo); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy); Staphylococcus spp. (sta); Gardnerella vaginalis (gva); Streptococcus spp. (str); Enterococcus faecalis (efa); Streptococcus, non-haemolytic (gamma) (sgm).
Pathogens 14 00696 g003
Figure 4. A clustering heatmap showing similarity in antibiotic susceptibility of isolated urogenital pathogens: A: Increasing susceptibility; C1: Group 1 cluster; C2: Group 2 cluster. The most active antibiotics are clustered in group one (C1), while the second cluster (C2) contains antibiotics that were less effective against the urogenital pathogens. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus (sau); Citrobacter koseri (cdi); Acinetobacter sp. (ac-); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. Saprophyticus (sap); Staphylococcus epidermidis (sep); Providencia sp. (prv); Citrobacter freundii (cfr); Serratia marcescens (sma); Enterobacter sp. (en-); Moraxella catarrhalis (bca); Morganella morganii ss. Morganii (mmo); Shigella sp. (shi); Providencia rettgeri (pre); Salmonella sp. (sal); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Francisella tularensis ss. Tularensis (ftu); Klebsiella pneumoniae ss. Rhinoscleromatis (krn); Neisseria meningitidis (nme); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy).
Figure 4. A clustering heatmap showing similarity in antibiotic susceptibility of isolated urogenital pathogens: A: Increasing susceptibility; C1: Group 1 cluster; C2: Group 2 cluster. The most active antibiotics are clustered in group one (C1), while the second cluster (C2) contains antibiotics that were less effective against the urogenital pathogens. (ci-); Klebsiella oxytoca (kox); Staphylococcus aureus (sau); Citrobacter koseri (cdi); Acinetobacter sp. (ac-); Enterococcus sp. (ent); Proteus vulgaris (pvu); Klebsiella pneumoniae (kpn); Proteus mirabilis (pmi); Staphylococcus saprophyticus ss. Saprophyticus (sap); Staphylococcus epidermidis (sep); Providencia sp. (prv); Citrobacter freundii (cfr); Serratia marcescens (sma); Enterobacter sp. (en-); Moraxella catarrhalis (bca); Morganella morganii ss. Morganii (mmo); Shigella sp. (shi); Providencia rettgeri (pre); Salmonella sp. (sal); Salmonella typhi (sat); Streptococcus viridans, alpha-hem. (svi); Francisella tularensis ss. Tularensis (ftu); Klebsiella pneumoniae ss. Rhinoscleromatis (krn); Neisseria meningitidis (nme); Staphylococcus, coagulase-negative (scn); Streptococcus pyogenes (spy).
Pathogens 14 00696 g004
Table 1. Prevalence of bacterial urogenital pathogens in samples from the Volta Regional Hospital and the Margret Marquart Catholic Hospital (N = 205).
Table 1. Prevalence of bacterial urogenital pathogens in samples from the Volta Regional Hospital and the Margret Marquart Catholic Hospital (N = 205).
OrganismCodeUrethral SwabUrineHVS SwabNumber of Isolates(%)
Gram-negativeEscherichia colieco 37145124.9
Klebsiella oxytocakox 144188.8
Klebsiella sp. *kl- 74115.4
Enterobacter sp. *en- 4373.4
Pseudomonas aeruginosapae 5 52.4
Citrobacter kosericdi 2242
Citrobacter sp. *ci- 3 31.5
Klebsiella pneumoniaekpn 3 31.5
Neisseria gonorrhoeaengo1 231.5
Citrobacter freundiicfr 1121
Salmonella Typhisat 1121
Morganella morganiimmo 110.5
Proteus mirabilispmi 1 10.5
Proteus vulgarispvu 1 10.5
Gram-positiveStaphylococcus aureussau1010244421.5
Streptococcus pyogenesspy1111136.3
Staphylococcus saprophyticussap 56115.4
Enterococcus sp. *ent 5383.9
Staphylococcus sp. *sta11462.9
Gardnerella vaginalisgva 331.5
Staphylococcus, coagulase-negativescn 2 21
Streptococcus sp. *str 1121
Enterococcus faecalisefa 1121
Streptococcus viridans, alpha-hem.svi 1 10.5
Streptococcus, non-haemolytic (gamma)sgm 1 10.5
* Other unspecified genera, HVS—high vaginal swabs.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Odoi, H.; Opoku, N.; Adusei, B.; Danquah, K.; Vordzogbe, G.; Mayer, D.; Hutton-Nyameaye, A.; Jato, J.; Somuah, S.O.; Orman, E.; et al. Trends of Antibiotic Resistance Patterns and Bacteriological Profiles of Pathogens Associated with Genitourinary Infections in Secondary Healthcare Facilities in the Volta Region of Ghana. Pathogens 2025, 14, 696. https://doi.org/10.3390/pathogens14070696

AMA Style

Odoi H, Opoku N, Adusei B, Danquah K, Vordzogbe G, Mayer D, Hutton-Nyameaye A, Jato J, Somuah SO, Orman E, et al. Trends of Antibiotic Resistance Patterns and Bacteriological Profiles of Pathogens Associated with Genitourinary Infections in Secondary Healthcare Facilities in the Volta Region of Ghana. Pathogens. 2025; 14(7):696. https://doi.org/10.3390/pathogens14070696

Chicago/Turabian Style

Odoi, Hayford, Naodiah Opoku, Brigham Adusei, Kenneth Danquah, Gilbert Vordzogbe, Divine Mayer, Araba Hutton-Nyameaye, Jonathan Jato, Samuel O. Somuah, Emmanuel Orman, and et al. 2025. "Trends of Antibiotic Resistance Patterns and Bacteriological Profiles of Pathogens Associated with Genitourinary Infections in Secondary Healthcare Facilities in the Volta Region of Ghana" Pathogens 14, no. 7: 696. https://doi.org/10.3390/pathogens14070696

APA Style

Odoi, H., Opoku, N., Adusei, B., Danquah, K., Vordzogbe, G., Mayer, D., Hutton-Nyameaye, A., Jato, J., Somuah, S. O., Orman, E., Ben, I. O., Aku, T. A., Sewornu, R., Panesar, P., Jani, Y. H., & Dodoo, C. C. (2025). Trends of Antibiotic Resistance Patterns and Bacteriological Profiles of Pathogens Associated with Genitourinary Infections in Secondary Healthcare Facilities in the Volta Region of Ghana. Pathogens, 14(7), 696. https://doi.org/10.3390/pathogens14070696

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop